The market-leading, trusted solution for processing, analyzing, and reporting adverse event cases originating in premarket and post-market drugs, biologics, vaccines, devices, and combination products. Transform your case management efficiency with innovative capabilities, such as built-in automation, workflow optimization, and conditional touchless processing.
Expertly manage rapidly increasing caseloads and changing regulations.
Built-in Argus automation features—for intake, case prioritization, field validations, letters, action items, coding, listedness, narratives, case lock, submission, and archiving—can reduce manual work by 50% or more.
You can depend on Argus, a mature, reliable solution providing proven compliance with drug, vaccine, and device regulations and standards in all regions of the world, including E2B(R3), E2B(R2), eVAERS, eMDR, MIR, and IDMP.
Argus Advanced Cloud includes Oracle Analytics, a powerful, flexible, AI-powered solution that empowers users to uncover new insights and make faster, more informed business decisions.
Since 1997, Oracle Argus has played a significant role in shaping medicinal product safety and now leads the way to next-generation multivigilance through data science-based innovation.
With so many new ways to report adverse events, companies can access more data on drug safety than ever before. As the number of adverse events rises, it’s crucial to have a system like Argus that can provide fast, high-quality insights at scale to drive the company—and industry—forward. Learn why automation is key in addressing these challenges.
More than10Mcases processed annually
More than400customers globally
More than70%of drug ICSRs in FDA FAERS
More than90%of vaccine ICSRs in FDA VAERS
How have Oracle's cloud offerings matured? What kind of service can customers expect within the Oracle SaaS suite? Hear from Steve Miranda, executive vice president for Oracle Applications Product Development, as he sits down with Constellation Research analyst Ray Wang.
Discover how our customers use Oracle Argus for safety case management.
In the 25 years since the birth of Argus, evolving technologies and pharmaceutical standards have significantly enhanced medicinal product safety. Current innovations in data science promise even greater future achievements. Discover key Argus milestones that have improved safety, and learn how Oracle continues to lead the way to next-generation multivigilance.
Engage with the Oracle Safety Consortium and participate in meetings, events, roundtable discussions, and working groups to accelerate safety solutions and help shape the future of the Argus, Empirica, and Safety One Intake solutions.
Learn how the Safety One platform addresses industry challenges by detecting risks earlier, automating processes, and increasing compliance with unified multivigilance.
Evolving technologies and pharmaceutical standards have significantly enhanced medicinal product safety in the last few decades, with innovations in data science promising even greater future achievements. Discover key milestones that have improved safety, and learn how Oracle continues to lead the way to next-generation multivigilance.
Medicinal product safety teams face enormous pressure to control ever-increasing caseloads, new sources of signal detection data, and changing regulations—all with flat budgets and resources. See how Oracle addresses these pharmacovigilance challenges.
Oracle Empirica is the market-leading solution for detecting, analyzing, and managing safety signals originating in premarket and post-market drugs, biologics, vaccines, devices, and combination products.
Oracle Life Sciences Safety One Intake leverages artificial intelligence to make safety case processing faster with better quality and compliance.
Habla con un miembro del equipo sobre las soluciones de Oracle para biomedicina y farmacia.
Escuche a científicos, médicos y líderes de la industria de farmacia, biotecnología y CRO, que están impulsando la innovación en biomedicina y farmacia.
Explora los contactos y recursos de soporte técnico.